# ITIL-168 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct05393635/  
OnCo record `nct05393635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ITIL-168 run by Instil Bio, withdrawn before enrolling.

## Summary

ITIL-168 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05393635 by Instil Bio, started 2022-08. Conditions recorded: Cervical Cancer, Head and Neck Squamous Cell Carcinoma and Non-small Cell Lung Cancer. Interventions recorded: ITIL-168.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05393635
- Phase: 1
- Setting: A Phase 1, Open-Label, Multicenter Study Evaluating the Safety, Feasibility, and Preliminary Efficacy of ITIL-168 With Pembrolizumab in Subjects With Advanced Solid Tumors
- Sponsor: Instil Bio

## Sources

- ClinicalTrials.gov NCT05393635: https://clinicaltrials.gov/study/NCT05393635

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [ITIL-168](https://onco.cc/drugs/itil-168/)
- companies: [Instil Bio](https://onco.cc/companies/instil-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05393635.json